Free Float 81,01 %
Shares Float 16,3 M
Shares Outstanding 20,11 M
OliX Pharmaceuticals,Inc
Share · KR7226950004 (XKOS)
AI-Powered Analysis
Fundamental Analysis
Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of OliX Pharmaceuticals,Inc
No Price
Closing Price XKOS 29.04.2026:
184.600,00 KRW
29.04.2026 06:30
Current Prices from OliX Pharmaceuticals,Inc
| Exchange | Ticker | Currency | Last Trade | Price | Daily Change |
|---|---|---|---|---|---|
 KOSDAQ |
226950.KQ
|
KRW
|
29.04.2026 06:30
|
184.600,00 KRW
| -700,00 KRW
-0,38 %
|
Share Float & Liquidity
Invested Funds
The following funds have invested in OliX Pharmaceuticals,Inc:
Fund | Vol. in million 49,61 | Percentage (%) 0,05 % |
Company Profile for OliX Pharmaceuticals,Inc Share
OliX Pharmaceuticals, Inc., a clinical stage biotechnology company, focuses on developing RNA interference (RNAi) therapeutics for dermal, ophthalmic, and pulmonary diseases. The company's products pipeline includes OLX101 for skin scar; OLX102 for skin whitening; OLX103, an atopic dermatitis product; OLX104 for hair loss; OLX105, an anti-wrinkle product; and OLX106 for diabetic foot ulcer. Its products pipeline also comprise OLX301 for age-related macular degeneration retinal fibrosis; OLX304 for retinitis pigmentosa; OLX201 for lung fibrosis; OLX202 for asthma; OLX203 for influenza; OLX401 for neuropathic pain; OLX701 for liver fibrosis; and OLX701 for cancer immunotherapy. The company has a collaboration agreement with Théa to develop SiRNA therapeutics for ophthalmic diseases; and a research collaboration with PCI Biotech Holding ASA. OliX Pharmaceuticals, Inc. was founded in 2010 and is based in Suwon, South Korea.
Company Data
Name OliX Pharmaceuticals,Inc
Company OliX Pharmaceuticals,Inc
Website
http://www.olixpharma.com
Primary Exchange
KOSDAQ
KOSDAQ
ISIN KR7226950004
Asset Class Share
Sector Healthcare
Industry Biotechnology
CEO Dong-Ki Lee
Market Capitalization 3.727 Mrd.
Country South Korea
Currency KRW
Employees 0,1 T
Address #1014 Gwanggyo Ace Tower1, 17, 16226 Suwon-si
IPO Date 2018-07-18
Dividends from 'OliX Pharmaceuticals,Inc'
| Ex-Date | Dividend per Share |
|---|---|
| 15.03.2022 | 0,29 KRW |
Stock Splits
| Date | Split |
|---|---|
| 03.12.2020 | 2:1 |
Ticker Symbols
| Name | Symbol |
|---|---|
| KOSDAQ | 226950.KQ |
More Shares
Investors who hold OliX Pharmaceuticals,Inc also have the following shares in their portfolio:
